Drug Drug Interaction Study for EYP001 With Entecavir
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03469583 |
Recruitment Status :
Completed
First Posted : March 19, 2018
Last Update Posted : July 26, 2018
|
Tracking Information | |||||||
---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | January 29, 2018 | ||||||
First Posted Date ICMJE | March 19, 2018 | ||||||
Last Update Posted Date | July 26, 2018 | ||||||
Actual Study Start Date ICMJE | February 12, 2018 | ||||||
Actual Primary Completion Date | June 20, 2018 (Final data collection date for primary outcome measure) | ||||||
Current Primary Outcome Measures ICMJE |
Area Under the Curve [ Time Frame: 24 hrs ] Area under the concentration-time curve from time 0 to 24 hours
|
||||||
Original Primary Outcome Measures ICMJE | Same as current | ||||||
Change History | |||||||
Current Secondary Outcome Measures ICMJE |
|
||||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||||
Current Other Pre-specified Outcome Measures | Not Provided | ||||||
Original Other Pre-specified Outcome Measures | Not Provided | ||||||
Descriptive Information | |||||||
Brief Title ICMJE | Drug Drug Interaction Study for EYP001 With Entecavir | ||||||
Official Title ICMJE | Study of the Drug Interaction of EYP001a With Entecavir in Healthy Subjects | ||||||
Brief Summary | This is a Phase 1, single-center, open-label, three subsequent dosing periods study to evaluate the drug-drug-interaction (DDI), pharmaco-kinetics (PK) and pharmacodynamics (PD), safety, and tolerability of a single dose of EYP100a combined with ETV in healthy men and women dosed in the morning under fasted conditions. | ||||||
Detailed Description | This is a Phase 1, single-center, open-label, three consecutive dosing periods study to evaluate the drug-drug interaction, PK, safety, tolerability and PD of a single dose of EYP100a combined with ETV in healthy men and women. Sixteen (16) adult male and female healthy participants 18 to 60 years of age inclusive are planned to participate in the study. Women of childbearing potential will be eligible to participate if she is non pregnant or non lactating and willing to use adequate contraception. All participants in the study will be monitored for safety after administration of the last dose of investigational product and with a follow up visit. The DDI, PK, PD, safety and tolerability of EYP001a and ETV will be assessed based on plasma-concentration profiles of EYP001a and ETV, FXR related PD markers and the types and frequency of treatment-emergent adverse events (TEAEs) reported, concomitant medication usage, and changes from baseline in physical examination (PE), vital signs, electrocardiogram (ECG), and standard clinical laboratory tests. |
||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 1 | ||||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment |
||||||
Condition ICMJE | Hepatitis B, Chronic | ||||||
Intervention ICMJE |
|
||||||
Study Arms ICMJE |
|
||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE |
16 | ||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||
Actual Study Completion Date ICMJE | July 20, 2018 | ||||||
Actual Primary Completion Date | June 20, 2018 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||
Sex/Gender ICMJE |
|
||||||
Ages ICMJE | 18 Years to 60 Years (Adult) | ||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Australia | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT03469583 | ||||||
Other Study ID Numbers ICMJE | EYP001-104 | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product |
|
||||||
IPD Sharing Statement ICMJE | Not Provided | ||||||
Current Responsible Party | Enyo Pharma | ||||||
Original Responsible Party | Same as current | ||||||
Current Study Sponsor ICMJE | Enyo Pharma | ||||||
Original Study Sponsor ICMJE | Same as current | ||||||
Collaborators ICMJE | CPR Pharma Services Pty Ltd, Australia | ||||||
Investigators ICMJE |
|
||||||
PRS Account | Enyo Pharma | ||||||
Verification Date | July 2018 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |